Fulgent Genetics, Inc. (FLGT) Tops Q3 EPS by 80c

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of $4.05, $0.80 better than the analyst estimate of $3.25. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $264 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2021 revenue of $930 million, versus the consensus of $948 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• RenovoRx regains Nasdaq minimum bid price compliance
• The Buckle (BKE) Tops Q2 EPS by 7c, Beats on Revenue